Trending Now - Eli Lilly Expands Portfolio With $3.25 Billion Kelonia Deal

WHO:

Boston.com - Eli Lilly, a pharmaceutical giant, is acquiring Kelonia Therapeutics, a small biotech company.

STAT - Bryan Roberts, a partner at the venture capital firm Venrock, provided insights into Kelonia's financial struggles.

WHAT:

Boston.com - Eli Lilly is acquiring Kelonia Therapeutics in a deal valued at $7 billion.

STAT - The acquisition by Eli Lilly is for $3.25 billion, with potential additional payments based on Kelonia achieving specified clinical, regulatory, and commercial milestones.

STAT - Kelonia Therapeutics has raised $60 million over the last five years and has faced financial difficulties, coming close to running out of cash three times.

WHERE:

Boston.com - The acquisition marks Eli Lilly's expansion in Massachusetts.

WHEN:

STAT - The acquisition announcement was made on Monday, April 18th, 2026.

WHY:

STAT - The acquisition is seen as a significant opportunity for Kelonia, which has struggled financially and is developing cell therapies for cancer and autoimmune diseases.

HOW:

STAT - The acquisition process included sharing original investment memos and slide decks used to launch Kelonia, then known as Elcano Therapeutics, providing insights into the biotech startup process.

(UPDATED April 20, 2026 23:20 UTC)

Eli Lilly is acquiring Kelonia Therapeutics in a deal valued at $7 billion, with an initial payment of $3.25 billion and potential additional payments tied to the company's future achievements. This acquisition, announced on Saturday, marks Eli Lilly's expansion in Massachusetts and comes as a significant opportunity for Kelonia, which has faced financial difficulties and has been developing cell therapies for cancer and autoimmune diseases. Bryan Roberts, a partner at Venrock, highlighted Kelonia's struggles, noting that the company raised $60 million over the past five years and nearly ran out of cash three times.